NCT07277231 2026-03-18
A Study to Investigate Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Acalabrutinib in Adults With Previously Untreated Chronic Lymphocytic Leukemia
BeOne Medicines
Phase 3 Recruiting
Clinical Trials
13 trialsNCT06136559 2026-03-16
BELLWAVE-011
Merck Sharp & Dohme LLC
Phase 3 Recruiting
NCT04075292 2026-03-05
Study of Acalabrutinib Versus Chlorambucil Plus Rituximab in Adult Subjects With Previously Untreated Chronic Lymphocytic Leukemia
AstraZeneca
Phase 3 Active not recruiting
NCT02972840 2026-02-18
A Study of BR Alone Versus in Combination With Acalabrutinib in Subjects With Previously Untreated MCL
Acerta Pharma BV
Phase 3 Active not recruiting
NCT05057494 2026-02-18
MAJIC
AstraZeneca
Phase 3 Active not recruiting
NCT02970318 2026-02-06
A Study of Acalabrutinib vs Investigator's Choice of Idelalisib Plus Rituximab or Bendamustine Plus Rituximab in R/R CLL
Acerta Pharma BV
Phase 3 Active not recruiting
NCT04008706 2025-12-01
ASSURE
AstraZeneca
Phase 3 Completed
NCT02477696 2025-11-20
Study of Acalabrutinib (ACP-196) Versus Ibrutinib in Previously Treated Participants With High Risk Chronic Lymphocytic Leukemia (CLL)
Acerta Pharma BV
Phase 3 Active not recruiting
NCT06428019 2025-11-05
A Study to Evaluate the Risk of Tumor Lysis Syndrome (TLS) in Adult Participants Receiving Oral Venetoclax in Combination With Intravenously Infused Obinutuzumab or Oral Acalabrutinib for Previously Untreated Chronic Lymphocytic Leukemia (CLL)
AbbVie
Phase 3 Recruiting
NCT02475681 2025-08-27
ElevateTN
Acerta Pharma BV
Phase 3 Active not recruiting
NCT04662255 2025-05-28
BRUIN-MCL-321
Eli Lilly and Company
Phase 3 Active not recruiting
NCT03836261 2024-12-27
AMPLIFY
Acerta Pharma BV
Phase 3 Active not recruiting
NCT05820841 2023-08-31
ARCHED
Universität des Saarlandes
Phase 3 Recruiting